Zachary Hornby, M.S., MBA

Zachary Hornby, M.S., MBA

CEO, Boundless Bio

Zachary (“Zach”) Hornby has served in executive and director roles for multiple private and
public biotechnology companies. He is currently CEO, President, and a Director at
Boundless Bio, a private, clinical stage, next-generation precision oncology company. He is
also a Director at Aardvark Therapeutics, Novome Biotechnologies, and Radionetics
Oncology. Prior to joining Boundless Bio, Zach was Chief Operating Officer at Ignyta, where
he oversaw development of the company’s portfolio of four clinical stage therapeutics and
was the team leader for the company’s lead program, RozlytrekTM (entrectinib), which was
the first drug in pharmaceutical history to garner the coveted BTD (FDA), PRIME (EMA)
and Sakigake (PMDA) designations. In that role, he also led the business development
process that resulted in Ignyta’s acquisition by Roche for $2 billion; after the Roche
acquisition, Zach served as the Ignyta site head where he was responsible for overseeing
the integration into Roche. Before assuming the COO role, Zach was Ignyta’s Chief Financial
Officer, helping the company go public and raise $120 million in capital. Prior to joining
Ignyta, Zach served in roles of increasing responsibility across business development,
marketing, new product planning, finance, and regulatory affairs at Fate Therapeutics,
Halozyme Therapeutics, Neurocrine Biosciences and Transkaryotic Therapeutics (“TKT;”
now the Human Genetic Therapies division within Takeda/Shire) and was a life sciences
consultant at L.E.K. Consulting.
Zach holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from
Stanford University and an MBA from Harvard Business School.